Advanced

The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis

Fransén Pettersson, Nina LU ; Deronic, Adnan LU ; Nilsson, Julia LU ; Hannibal, Tine LU ; Hansen, Lisbeth LU ; Schmidt-Christensen, Anja LU ; Ivars, Fredrik LU and Holmberg, Dan LU (2018) In PLoS ONE 13(9).
Abstract
Quinoline-3-carboxamides (Q substances) are small molecule compounds with anti-inflammatory properties. In this study, we used one of these substances, Paquinimod, to treat a novel model for chronic liver inflammation and liver fibrosis, the NOD-Inflammation Fibrosis (N-IF) mouse. We show that treatment of N-IF mice significantly reduced inflammation and resulted in the regression of fibrosis, even when the treatment was initiated after onset of disease. The reduced disease phenotype was associated with a systemic decrease in the number and reduced activation of disease-promoting transgenic natural killer T (NKT)-II cells and their type 2-cytokine expression profile. Paquinimod treatment also led to a reduction of CD115+ Ly6Chi monocytes... (More)
Quinoline-3-carboxamides (Q substances) are small molecule compounds with anti-inflammatory properties. In this study, we used one of these substances, Paquinimod, to treat a novel model for chronic liver inflammation and liver fibrosis, the NOD-Inflammation Fibrosis (N-IF) mouse. We show that treatment of N-IF mice significantly reduced inflammation and resulted in the regression of fibrosis, even when the treatment was initiated after onset of disease. The reduced disease phenotype was associated with a systemic decrease in the number and reduced activation of disease-promoting transgenic natural killer T (NKT)-II cells and their type 2-cytokine expression profile. Paquinimod treatment also led to a reduction of CD115+ Ly6Chi monocytes and CD11b+ F4/80+ CD206+ macrophages. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
PLoS ONE
volume
13
issue
9
publisher
Public Library of Science
external identifiers
  • scopus:85052863945
  • pmid:30183741
ISSN
1932-6203
DOI
10.1371/journal.pone.0203228
language
English
LU publication?
yes
id
ff8147bc-6d5f-4753-a118-c3c67454dc2e
date added to LUP
2018-09-18 11:08:50
date last changed
2019-09-17 04:38:41
@article{ff8147bc-6d5f-4753-a118-c3c67454dc2e,
  abstract     = {Quinoline-3-carboxamides (Q substances) are small molecule compounds with anti-inflammatory properties. In this study, we used one of these substances, Paquinimod, to treat a novel model for chronic liver inflammation and liver fibrosis, the NOD-Inflammation Fibrosis (N-IF) mouse. We show that treatment of N-IF mice significantly reduced inflammation and resulted in the regression of fibrosis, even when the treatment was initiated after onset of disease. The reduced disease phenotype was associated with a systemic decrease in the number and reduced activation of disease-promoting transgenic natural killer T (NKT)-II cells and their type 2-cytokine expression profile. Paquinimod treatment also led to a reduction of CD115+ Ly6Chi monocytes and CD11b+ F4/80+ CD206+ macrophages.},
  articleno    = {e0203228},
  author       = {Fransén Pettersson, Nina and Deronic, Adnan and Nilsson, Julia and Hannibal, Tine and Hansen, Lisbeth and Schmidt-Christensen, Anja and Ivars, Fredrik and Holmberg, Dan},
  issn         = {1932-6203},
  language     = {eng},
  month        = {09},
  number       = {9},
  publisher    = {Public Library of Science},
  series       = {PLoS ONE},
  title        = {The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis},
  url          = {http://dx.doi.org/10.1371/journal.pone.0203228},
  volume       = {13},
  year         = {2018},
}